• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Wegovy Maker Novo Nordisk, Akero Therapeutics, Eli Lilly, Athena Consumer Acquisition, Tesla: Why These 5 Stocks Are Trending Today

    10/10/23 9:56:58 PM ET
    $ACAQ
    $AKRO
    $LLY
    $NVO
    Blank Checks
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACAQ alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday. The Dow traded up 0.4% to 33,739.30 while the NASDAQ rose 0.58% to 13,562.84. The S&P 500 also rose, gaining 0.52% to 4,358.24.

    These are the top stocks that gained the attention of retail traders and investors throughout the day:

    Akero Therapeutics Inc (NASDAQ:AKRO) saw a significant drop of 62.61%, closing at $18.15, with an intraday high of $19.87 and a low of $14.76, marking a 52-week low. The 36-week analysis of its Phase 2b SYMMETRY study revealed that efruxifermin was not statistically significant in improving liver scarring without worsening of NASH, causing the shares to tumble.

    Eli Lilly And Co (NYSE:LLY) closed the day with a 1.32% increase at $579.31, reaching an intraday high of $585.95 and a low of $569.73. The 52-week high stands at $601.84 with a low of $309.2. Hampus Hillerstrom, CEO of LuMind IDSC, is advocating for access to Alzheimer’s drugs made by Eli Lilly, despite opposition from neurologists who cite potential safety risks.

    Athena Consumer Acquisition Corp (NASDAQ:ACAQ) experienced a 10.53% surge, closing at $6.3 with a high of $6.45 and a low of $5.54. The 52-week range is $12.8 to $4.28. The company announced a special meeting of its stockholders to approve an amendment allowing an extension for consummating a business combination.

    Novo Nordisk A/S (NYSE:NVO) saw a 1.03% increase, closing at $93.01, with an intraday high of $93.44 and a low of $91.9. The 52-week high is $100.88 and the low is $50.45. A survey conducted by Accolade Inc and Savanta revealed a growing willingness among U.S. employers to include GLP-1 drugs like Wegovy in their health coverage plans.

    Tesla Inc (NASDAQ:TSLA) increased by 1.52%, closing at $263.62, with a high of $268.94 and a low of $257.65. The 52-week range is $299.29 to $101.81. The company’s Model Y recently passed the two million unit sales milestone, positioning it to potentially become the bestselling electric vehicle of all time.

    Photo by Phongphan on Shutterstock

    Prepare for the day's trading with top premarket movers and news by Benzinga.


    Engineered by Benzinga Neuro, Edited by Shivdeep Dhaliwal


    The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


    Get the next $ACAQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAQ
    $AKRO
    $LLY
    $NVO

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    3/26/2026Peer Perform
    Wolfe Research
    Novo Nordisk A/S
    $NVO
    3/18/2026Underperform
    Bernstein
    Novo Nordisk A/S
    $NVO
    3/18/2026$175.00Outperform
    Bernstein
    Eli Lilly and Company
    $LLY
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    Novo Nordisk A/S
    $NVO
    3/10/2026$42.00Buy → Hold
    TD Cowen
    Tesla Inc.
    $TSLA
    3/4/2026$460.00Buy
    BofA Securities
    Novo Nordisk A/S
    $NVO
    3/3/2026$40.00Underweight → Equal-Weight
    Morgan Stanley
    Novo Nordisk A/S
    $NVO
    3/2/2026$41.00Buy → Neutral
    Goldman
    More analyst ratings

    $ACAQ
    $AKRO
    $LLY
    $NVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Novo Nordisk A/S

    Wolfe Research initiated coverage of Novo Nordisk A/S with a rating of Peer Perform

    3/26/26 9:00:52 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Novo Nordisk A/S

    Bernstein initiated coverage of Novo Nordisk A/S with a rating of Underperform

    3/18/26 3:58:44 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Novo Nordisk A/S with a new price target

    Bernstein initiated coverage of Novo Nordisk A/S with a rating of Outperform and set a new price target of $175.00

    3/18/26 1:57:24 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AKRO
    $LLY
    $NVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

    3/8/24 2:00:18 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AKRO
    $LLY
    $NVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis

    In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years75% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 78% experienced significant itch relief (Pruritus NRS ≤4), one of the most bothersome symptoms for patients80% of patients achieved durable results without the need for topical corticosteroidsINDIANAPOLIS, March 27, 2026 /PRNewswire/ -- New long-term data show Eli Lilly and Company's (NYSE:LLY) EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis (eczema) in an open-

    3/27/26 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

    Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy® HD (~19% regardless of whether patients stayed on treatment**) in the STEP UP trial1In the STEP UP trial, about one in three trial participants taking Wegovy® HD achieved 25% weight loss or higher1This approval for Wegovy® further expands its already robust label inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicinesPLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.

    3/19/26 12:04:00 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

    For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) No weight loss plateau was observed with retatrutide, with participants continuing their weight loss trajectory through 40 weeksINDIANAPOLIS, March 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise. The trial enrolled adults diagn

    3/19/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AKRO
    $LLY
    $NVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.17% to 2,976 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    3/17/26 4:32:31 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Luciano Juan R was granted 16 shares, increasing direct ownership by 0.10% to 16,817 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    3/17/26 4:31:37 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fyrwald J Erik was granted 10 shares, increasing direct ownership by 0.01% to 75,259 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    3/17/26 4:30:41 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AKRO
    $LLY
    $NVO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Tesla Inc.

    SCHEDULE 13G/A - Tesla, Inc. (0001318605) (Subject)

    3/27/26 1:36:06 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    3/27/26 7:47:17 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    3/27/26 6:33:06 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AKRO
    $LLY
    $NVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Musk Elon bought $999,959,042 worth of shares (2,568,732 units at $389.28) (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    9/15/25 6:01:19 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AKRO
    $LLY
    $NVO
    Financials

    Live finance-specific insights

    View All

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

    INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.   The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into h

    1/21/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tesla Fourth Quarter 2025 Production, Deliveries & Deployments

    In the fourth quarter, we produced over 434,000 vehicles, delivered over 418,000 vehicles and deployed 14.2 GWh of energy storage products – a record for deployments. Thank you to all of our customers, employees, suppliers, shareholders and supporters who helped us achieve these results. Q4 2025   Production Deliveries Subject to operating lease accounting Model 3/Y 422,652 406,585 3% Other Models 11,706 11,642 5% Total 434,358 418,227 3% 2025   Production Deliveries Model 3/Y 1,600,767 1,585,279 Other Models 53,900 50,850

    1/2/26 9:07:00 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $ACAQ
    $AKRO
    $LLY
    $NVO
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AKRO
    $LLY
    $NVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

    SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

    11/14/24 3:59:41 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

    SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

    11/14/24 1:22:38 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Akero Therapeutics Inc.

    SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)

    11/14/24 6:51:23 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care